Welcome to our dedicated page for Crescent Biopharma news (Ticker: cbio), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crescent Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crescent Biopharma's position in the market.
Crescent Biopharma (Nasdaq: CBIO) announced inducement equity option awards approved January 29, 2026, granting an aggregate of 117,339 options to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan.
Options have a 10-year term, exercise price of $10.15, and standard four-year vesting with monthly vesting thereafter.
Crescent Biopharma (Nasdaq: CBIO) announced IND clearances for two oncology candidates: CR-001 (PD-1 x VEGF bispecific) cleared by the U.S. FDA and CR-003 (ITGB6-targeted ADC/SKB105) approved by China NMPA CDE via partner Kelun-Biotech. Crescent plans a global Phase 1/2 ASCEND trial for CR-001 in first-line and previously treated solid tumor patients, targeting enrollment of up to 290 participants and on track to start in Q1 2026. Proof-of-concept data from ASCEND is anticipated in Q1 2027. Crescent expects four clinical trials across its portfolio to initiate in 2026. The strategic collaboration with Kelun-Biotech defines ex-China and Greater China commercialization rights for the two programs.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards to three non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The Board approved an aggregate of 129,626 options on December 13, 2025, and the options were granted on December 15, 2025. Each option has a 10-year term and an exercise price of $13.21, equal to the Nasdaq closing price on December 15, 2025. Vesting is 25% after the first anniversary of each employee’s start date, then monthly at 1/48th thereafter, subject to continuous service and the Inducement Plan terms.
Crescent Biopharma (Nasdaq: CBIO) announced an exclusive strategic partnership with Kelun-Biotech and a $185 million private placement expected to close on or about December 8, 2025. The financing of 13,795,685 ordinary shares at $13.41 per share (and pre-funded warrants) is expected to provide cash runway into 2028. The collaboration grants Kelun rights to CR-001 in Greater China and grants Crescent rights to SKB105 (CR-003) outside Greater China.
Pipeline milestones: global Phase 1/2 start for CR-001 in Q1 2026 with proof-of-concept data in Q1 2027; CR-003 (SKB105) Phase 1/2 in Q1 2026 with PoC in Q1 2027; CR-002 IND planned mid-2026 with PoC in H2 2027; initial ADC combination data expected by year-end 2027.
Crescent Biopharma (Nasdaq: CBIO) and Kelun-Biotech (6990.HK) announced a strategic oncology partnership to develop and commercialize Crescent’s CR-001 (PD-1 x VEGF bispecific) and Kelun’s SKB105 (ITGB6-directed ADC).
Key terms: CR-001 and SKB105 are planned to enter Phase 1/2 monotherapy trials in Q1 2026; Kelun receives US$80M upfront plus up to US$1.25B in milestones and tiered royalties for SKB105 rights in Greater China; Crescent receives US$20M upfront plus up to US$30M in milestones and royalties for CR-001 rights outside Greater China. The collaboration includes monotherapy and combination development and cross‑territory exclusive commercial rights.
Crescent Biopharma (Nasdaq: CBIO) announced that its independent Compensation Committee approved inducement option awards for eight non-executive employees totaling 451,448 options, approved on November 14, 2025.
The options have a 10-year term, an exercise price of $13.02 per share (Crescent's Nasdaq closing price on November 14, 2025), and vest 25% on the first anniversary of each employee's start date with the remainder vesting 1/48th monthly thereafter, subject to continuous service and the Inducement Plan terms. The grants were described as material to each employee's acceptance under Nasdaq Listing Rule 5635(c)(4).
Crescent Biopharma (Nasdaq: CBIO) reported third quarter 2025 results and pipeline progress on Nov 6, 2025. Key clinical milestones include an IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025 to support a global Phase 1 trial starting in Q1 2026, with proof-of-concept data expected in H2 2026. Preclinical CR-001 data will be presented at SITC on Nov 7, 2025. Crescent also plans an IND for CR-002 (ADC) in mid-2026 and continues development of CR-003.
Financials: cash of $133.3M as of Sept 30, 2025 (expected to fund operations through 2027), R&D expense of $20.3M, G&A expense of $5.5M, net loss of $24.6M ($1.27 per share) for Q3 2025, and ~19.6M shares outstanding.
Crescent Biopharma (Nasdaq: CBIO) announced management will present at three investor conferences in November 2025: a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Nov 11, 2025 at 8:00 a.m. ET in Boston; a fireside chat at the Stifel 2025 Healthcare Conference on Nov 12, 2025 at 1:20 p.m. ET in New York; and a fireside chat at the Jefferies Global Healthcare Conference on Nov 19, 2025 at 9:30 a.m. GMT (4:30 a.m. ET) in London.
Each presentation will be livestreamed from Crescent's investor website and a replay will be accessible for 90 days.
Crescent Biopharma (NASDAQ: CBIO) will present preclinical data for CR-001, a tetravalent PD-1 x VEGF bispecific antibody, at the Society for Immunotherapy of Cancer 40th Annual Meeting on November 7-9, 2025.
Key points: CR-001 showed cooperative pharmacology in vitro with increased PD-1 binding in the presence of VEGF, augmented PD-1/PD-L1 blockade, enhanced T-cell activation, potent anti-tumor activity in a xenograft model, and good tolerability plus robust PD-1 receptor occupancy in non-human primates. Crescent says an IND submission is on track for Q4 2025 to support a global Phase 1 trial planned to begin in Q1 2026. The poster (Abstract 1185) will be available on SITC and on Crescent’s website beginning 9:00 a.m. ET on the presentation day.
Crescent Biopharma (Nasdaq: CBIO), a biotechnology company focused on cancer therapies, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4, 2025, at 1:00 p.m. ET, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35 p.m. ET. Both events will take place in New York.
Webcasts will be available on the company's investor relations website, with replays accessible for 90 days.
FAQ
What is the current stock price of Crescent Biopharma (cbio)?
What is the market cap of Crescent Biopharma (cbio)?
